Current Report Filing (8-k)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event
reported): December 30, 2020
ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Commission File Number)
20 Commerce Drive (Suite 135), Cranford, New Jersey
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
material pursuant to Rule 14a-12 under the Exchange Act (17
communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
of Each Class
of Each Exchange on Which Registered
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company ¨
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
||Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
Resignation of Andrew Rackear as Chief Executive Officer and
On December 30, 2020, Andrew Rackear, Chief Executive Officer and
Secretary of Enzon Pharmaceuticals, Inc. (the “Company”),
notified the Company’s Board of Directors (the “Board”) that
he is retiring, effective February 26, 2021. Mr. Rackear will
continue to serve in such roles until such date.
Following his retirement, Mr. Rackear will be available as a
consultant to the Company.
Appointment of Richard L. Feinstein as Chief Executive
Officer and Secretary
On December 30, 2020, the Board appointed Richard L. Feinstein,
Vice President-Finance and Chief Financial Officer since 2013, as
Chief Executive Officer and Secretary of the Company, effective
February 26, 2021. Following such appointment, Mr. Feinstein,
77, will also continue to serve as Chief Financial Officer.
Mr. Feinstein has served as Vice President - Finance and Principal
Chief Financial Officer since December 2013. Mr. Feinstein is a
retired partner of KPMG LLP and currently a private consultant
providing management and financial advice to clients in a variety
of industries. From 2015 to 2019, he provided financial consulting
services to General Cannabis Corp, a public company. During July
2016, he provided consulting services to Hamaspik, Inc. Mr.
Feinstein has served on boards of both publicly-held and
not-for-profit enterprises. Mr. Feinstein, a certified public
accountant, received a BBA degree from Pace University. Mr.
Feinstein also served in the United States Marine Corps.
Mr. Feinstein currently serves the Company on a consulting basis at
a rate of $325 per hour for each hour worked, together with
reimbursement for reasonable expenses incurred in performing his
services, pursuant to the terms of an independent contractor
agreement, as amended. Said compensation will remain the same under
his new role.
There is no arrangement or understanding between Mr. Feinstein and
any other persons pursuant to which Mr. Feinstein was selected as
the Company's Chief Executive Officer and Secretary that would
require disclosure under Item 401(b) of Regulation S-K. Mr.
Feinstein does not have any family relationship with any of the
Company's directors or executive officers that would require
disclosure under Item 401(d) of Regulation S-K. The Company is not
aware of any relationship or transaction in which Mr. Feinstein has
or will have an interest, or was or is a party, that would require
disclosure under Item 404(a) of Regulation S-K.
On January 4, 2021, the Company issued a press release announcing
Mr. Feinstein’s additional appointments as Chief Executive Officer
and Secretary, effective February 26, 2021, a copy of which is
attached to this Current Report on Form 8-K as Exhibit 99.1.
Change in Richard L. Feinstein's Title
On December 30, 2020, the Board approved a change in Richard L.
Feinstein’s title from Vice President-Finance and Chief Financial
Officer, to Chief Executive Officer, Chief Financial Officer, and
Secretary, effective February 26, 2021.
||Financial Statements and
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
January 4, 2021
/s/ Andrew Rackear
Chief Executive Officer and Secretary